Sharon M. Joyce Director
Collaboration with Rowan Osteopathic School of Medicine
The DLPS, DCA, and the Rowan University School of Osteopathic Medicine (“Rowan SOM”) partnered as of April 15, 2019 to create the New Jersey Opioid Medical Education Program, in order to provide health care professionals with an avenue to meet statutorily mandated continuing education requirements on opioid related topics. This project was funded by Governor Phil Murphy’s fiscal year 2019 budget, at a cost of $941,582.31. Current law requires the following health care professionals to complete at least one credit of continuing education on topics concerning prescription opioid drugs, including the risks and signs of opioids abuse, addiction and diversion: physicians, dentists, physician assistants, certified nurse midwives, nurses, pharmacists, podiatrists, optometrists, social workers, psychologists, professional counselors, marriage and family therapists, veterinarians and athletic trainers. Rowan SOM, in collaboration with NJ CARES, has produced six educational modules aligned with these statutory requirements, and available to licensees in both a live and enduring format, at a cost of $7.
Module 1 is directed at prescribers, and provides training on best practices in opioid prescribing and compliance with state and federal regulation. Module 2 addresses best practices for pharmacists in opioid dispensing, counseling patients and caregivers, opioid storage and disposal, and halting abuse and diversion. Module 3 is directed at mental health professionals, and addresses best practices in treating patients suffering from opioid use disorder, including integrated behavioral health services and recovery supports. Module 4 addresses the supportive role of nurses and athletic trainers in caring for patients on opioids or suffering with substance use disorder. Module 5 focuses on the use of screening methodology, particularly SBIRT, to identify and refer at risk patients. Module 6 provides a comprehensive review of medication-assisted treatment (“MAT”) for substance use disorder in the era of COVID-19, and addresses the effectiveness of MAT, the use of telemedicine in prescribing MAT, and overcoming stigma and barriers to MAT for vulnerable populations.
Click here to register for the New Jersey Opioid Medical Education Program: http://bit.ly/njcaresmodules